Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19661323 | 0.85 | MMP1 (0.42) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL24584764 | 0.84 | ABCB1 (0.41) | SMN1; SMN2HDAC7MEN1ALDH1A1KMT2A | |
| SCHEMBL29697806 | 0.84 | MMP1 (0.41) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL29859782 | 0.84 | PDE4B (0.37) | ESR2GRIA2GRIA4HSD11B1 | |
| SCHEMBL24584094 | 0.84 | PDE4B (0.37) | ESR2GRIA2GRIA4HSD11B1 | |
| SCHEMBL1126905 | 0.82 | SMN1; SMN2 (0.36) | SMN1; SMN2THRBHSD17B10HDAC7PTGS1 | |
| SCHEMBL23488097 | 0.82 | THRB (0.40) | SMN1; SMN2THRBPTGS1MEN1ALDH1A1 | |
| SCHEMBL24584060 | 0.82 | HSD11B1 (0.38) | MEN1ALDH1A1KMT2AGRIA2GRIA4 | |
| SCHEMBL31585835 | 0.81 | GABRA1 (0.45) | MMP1MMP7MMP9MMP8MMP13 | |
| SCHEMBL15162096 | 0.81 | THRB (0.39) | SMN1; SMN2GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497397-B2 | Pyrrole compounds useful as antifungals | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2025-12-16 | — | — | US | disclosed |
| EP-4071137-B1 | NOVEL PYRROLE COMPOUND | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2025-10-15 | — | — | EP | disclosed |
| US-20240327423-A1 | A SERIES OF PYRROLE DERIVATIVES AND THEIR PREPARATION METHOD AND THERAPEUTIC USE | Shenzhen Sungening Biological Co., Ltd (CN) | 2024-10-03 | — | — | US | disclosed |
| US-11819503-B2 | Method of treating coccidioides infection | F2G LTD (GB) | 2023-11-21 | — | — | US | disclosed |
| US-11819503-B2 | Method of treating coccidioides infection | F2G LTD (GB) | 2023-11-21 | — | — | US | disclosed |
| US-11819503-B2 | Method of treating coccidioides infection | F2G LTD (GB) | 2023-11-21 | — | — | US | disclosed |
| EP-4265621-A1 | PYRROLE DERIVATIVE, AND PREPARATION METHOD AND USE THEREFOR | Shenzhen Sungening Bio-Medical Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-4265621-A1 | PYRROLE DERIVATIVE, AND PREPARATION METHOD AND USE THEREFOR | Shenzhen Sungening Bio-Medical Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-109982704-B | Pharmaceutical preparation | F2G有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-114206836-B | Novel pyrrole compounds | 微境生物医药科技(上海)有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2016079536-A1 | ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| WO-2016079536-A1 | ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2016-05-26 | — | — | WO | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2626361-A1 | Pyrrole antifungal agents | F2G Limited (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327423-A1 | A SERIES OF PYRROLE DERIVATIVES AND THEIR PREPARATION METHOD AND THERAPEUTIC USE | DHODH, PPOX, HPD | MMP1 1358/4885MMP7 2143/4885MMP9 1247/4885 |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | MMP1 1633/4885MMP7 2734/4885MMP9 3303/4885 |
| US-12497397-B2 | Pyrrole compounds useful as antifungals | PYCR1, CYP51A1, DPM1 | MMP1 3313/4885MMP7 3562/4885MMP9 3724/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | MMP1 1633/4885MMP7 2734/4885MMP9 3303/4885 |
| US-11819503-B2 | Method of treating coccidioides infection | DPM1, OAT, OTC | MMP1 377/4885MMP7 2554/4885MMP9 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.